Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination (Q38541624)

4 September 2017

1 reference

title

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination (English)

1 reference

4 September 2017

Jonathan C Cho

1

1 reference

4 September 2017

Mallory A Fiorenza

series ordinal

2

1 reference

4 September 2017

Sandy J Estrada

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 July 2015

1 reference

4 September 2017

1 reference

4 September 2017

35

1 reference

4 September 2017

7

1 reference

4 September 2017

701-715

1 reference

Combating antimicrobial resistance: policy recommendations to save lives

4 September 2017

1 reference

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

21 January 2018

1 reference

Progress and challenges in implementing the research on ESKAPE pathogens

21 January 2018

1 reference

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

21 January 2018

1 reference

Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures

21 January 2018

1 reference

Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria

21 January 2018

1 reference

Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

21 January 2018

1 reference

Antipseudomonal antibiotics.

21 January 2018

1 reference

Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

21 January 2018

1 reference

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

21 January 2018

1 reference

Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205.

21 January 2018

1 reference

Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure

21 January 2018

1 reference

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients

21 January 2018

1 reference

Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities

21 January 2018

1 reference

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

21 January 2018

1 reference

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals

21 January 2018

1 reference

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients

21 January 2018

1 reference

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions

21 January 2018

1 reference

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses

21 January 2018

1 reference

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

21 January 2018

1 reference

Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam

21 January 2018

1 reference

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

21 January 2018

1 reference

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

21 January 2018

1 reference

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms

21 January 2018

1 reference

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

21 January 2018

1 reference

Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response

21 January 2018

1 reference

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1609

1 reference

4 September 2017

1 reference